Compared side by side
Retatrutide vs BPC-157: how they differ
The short answer
They do different jobs: retatrutide is a weekly agonist of three receptors, GLP-1, GIP and glucagon, run for weight loss, and BPC-157 is a peptide derived from a protein in human gastric juice that, in animal studies, protects the gut lining and speeds tendon, ligament and muscle repair. Retatrutide’s top dose averaged about 25–28% weight loss at 80 weeks in phase 3, and it isn’t approved yet; BPC-157’s human studies so far are three small uncontrolled pilots. Commonly reported: GI side effects after each retatrutide step-up, and a calmer gut on BPC-157, which the library lists beside retatrutide for GI support.
Side by side
| Compared | Retatrutide | BPC-157 |
|---|---|---|
| Category | Metabolic & GLP-1 | Healing & recovery |
| Also known as | LY3437943 | Body Protection Compound 157, BPC157 |
| What it is | The first triple agonist to reach phase 3: it activates GLP-1, GIP and glucagon receptors at once, and the glucagon arm adds extra calorie burn (shown in mice). | A peptide derived from a protective protein in your stomach. |
| How it works | Triple GIP/GLP-1/glucagon receptor agonist. Produces large weight loss through appetite suppression and improved metabolic function; the glucagon arm adds energy expenditure, shown so far in mice. Its trials step the dose up every 4 weeks because GI side effects rise with the dose; in phase 2 they were milder with a 2 mg start than a 4 mg one. | Synthetic pentadecapeptide derived from a protein in human gastric juice. In animal studies it promotes angiogenesis, speeds tendon, ligament and muscle healing, modulates dopamine and serotonin systems, and protects the gut lining. |
| Commonly reported | Appetite suppression even stronger than tirzepatide, GI side effects after each step-up, and a higher resting heart rate. Its top dose averaged about 25–28% weight loss at 80 weeks in phase 3; it isn't approved yet. | Faster recovery from tendon and ligament injuries, and a calmer gut. It's one of the most widely used peptides in the community; the human studies so far are three small uncontrolled pilots. |
| Studied range | Research range: 1–12 mg, starting dose 2 mg. Studied in research — not a recommendation. | Research range: 200–500 mcg. Studied in research — not a recommendation. |
| How often | Weekly | Once or twice daily |
| Half-life | ~6 days (measured in early trials in people) | ~4–6 hours (community estimate for SubQ; not measured in people: in rats and dogs it cleared in under 30 minutes) |
| Route | SubQ injection | SubQ injection, IM injection, Oral (less studied) |
| Typical run | Phase 3 trials use continuous dosing. Community mirrors this — long-term with slow titration. | Typically 4–12 weeks. Many run until injury resolves then stop. Some run indefinitely at lower doses. Opinions vary widely. |
| Evidence | Established: clinical trials or FDA-approved use exists | Emerging: primarily preclinical / limited human data |
| Common side effects | Nausea, vomiting, diarrhea, constipation, decreased appetite, fatigue, abdominal pain | Nausea (rare), injection site irritation, vivid dreams, dizziness |
- Category
- RetatrutideMetabolic & GLP-1
- BPC-157Healing & recovery
- Also known as
- RetatrutideLY3437943
- BPC-157Body Protection Compound 157, BPC157
- What it is
- RetatrutideThe first triple agonist to reach phase 3: it activates GLP-1, GIP and glucagon receptors at once, and the glucagon arm adds extra calorie burn (shown in mice).
- BPC-157A peptide derived from a protective protein in your stomach.
- How it works
- RetatrutideTriple GIP/GLP-1/glucagon receptor agonist. Produces large weight loss through appetite suppression and improved metabolic function; the glucagon arm adds energy expenditure, shown so far in mice. Its trials step the dose up every 4 weeks because GI side effects rise with the dose; in phase 2 they were milder with a 2 mg start than a 4 mg one.
- BPC-157Synthetic pentadecapeptide derived from a protein in human gastric juice. In animal studies it promotes angiogenesis, speeds tendon, ligament and muscle healing, modulates dopamine and serotonin systems, and protects the gut lining.
- Commonly reported
- RetatrutideAppetite suppression even stronger than tirzepatide, GI side effects after each step-up, and a higher resting heart rate. Its top dose averaged about 25–28% weight loss at 80 weeks in phase 3; it isn't approved yet.
- BPC-157Faster recovery from tendon and ligament injuries, and a calmer gut. It's one of the most widely used peptides in the community; the human studies so far are three small uncontrolled pilots.
- Studied range
- RetatrutideResearch range: 1–12 mg, starting dose 2 mg. Studied in research — not a recommendation.
- BPC-157Research range: 200–500 mcg. Studied in research — not a recommendation.
- How often
- RetatrutideWeekly
- BPC-157Once or twice daily
- Half-life
- Retatrutide~6 days (measured in early trials in people)
- BPC-157~4–6 hours (community estimate for SubQ; not measured in people: in rats and dogs it cleared in under 30 minutes)
- Route
- RetatrutideSubQ injection
- BPC-157SubQ injection, IM injection, Oral (less studied)
- Typical run
- RetatrutidePhase 3 trials use continuous dosing. Community mirrors this — long-term with slow titration.
- BPC-157Typically 4–12 weeks. Many run until injury resolves then stop. Some run indefinitely at lower doses. Opinions vary widely.
- Evidence
- RetatrutideEstablished: clinical trials or FDA-approved use exists
- BPC-157Emerging: primarily preclinical / limited human data
- Common side effects
- RetatrutideNausea, vomiting, diarrhea, constipation, decreased appetite, fatigue, abdominal pain
- BPC-157Nausea (rare), injection site irritation, vivid dreams, dizziness
Typical run: Community practice — opinions vary. Not a clinical recommendation.

Model. Individual results vary.
Week by week
Each entry’s cards by day window, as the compound pages show them. Day 1 is the day you start it.
Retatrutide
- Day 1–28 · 2 mg Triple-agonist is kicking in
- Day 29–84 · 4 mg Dose-response steepens
- Day 60+ · 9 mg Watch for dysesthesia at higher doses
- Day 84+ This is a maintenance medication, not a course
- Day 85–168 · 8 mg Higher steps: strong satiety
- Day 169–336 No plateau yet at week 48
- Day 337–476 Phase 3 territory: the headline numbers
BPC-157
- Day 1–7 Week one: early hints, for some
- Day 7–14 Pain often starts to ease
- Day 14–21 Pain often eases by week three
- Day 21–28 Many report a calmer gut
- Day 28–42 The slower part of repair
- Day 42–56 Six weeks in: taking stock
- Day 84+ Past week 12, the data runs thin
Together or one or the other
Retatrutide and BPC-157 are a common stack: retatrutide lists BPC-157 among its common stacks.
Community · Retatrutide
Why people add BPC-157 to Reta
Titrating up on Reta can be rough on the gut — especially the later transitions — and BPC-157 is added to ease it. Commonly reported: smoother step-ups with fewer GI side effects. One of the most common Reta pairings.
Questions people ask
How long do retatrutide and BPC-157 last?
The half-life of retatrutide is ~6 days (measured in early trials in people). The half-life of BPC-157 is ~4–6 hours (community estimate for SubQ; not measured in people: in rats and dogs it cleared in under 30 minutes).
How often are retatrutide and BPC-157 taken?
Retatrutide: weekly. Route: SubQ injection. BPC-157: once or twice daily. Routes: SubQ injection, IM injection, oral (less studied).
How are retatrutide and BPC-157 dosed in research?
The research range for retatrutide is 1–12 mg, with a 2 mg starting dose. The research range for BPC-157 is 200–500 mcg. Studied in research — not a recommendation.
What are the common side effects of retatrutide and BPC-157?
For retatrutide, the library lists: nausea, vomiting, diarrhea, constipation, decreased appetite, fatigue, abdominal pain. For BPC-157: nausea (rare), injection site irritation, vivid dreams, dizziness.
Are retatrutide and BPC-157 taken together?
Retatrutide and BPC-157 are a common stack: retatrutide lists BPC-157 among its common stacks. Titrating up on Reta can be rough on the gut — especially the later transitions — and BPC-157 is added to ease it. Commonly reported: smoother step-ups with fewer GI side effects. One of the most common Reta pairings.